These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

57 related items for PubMed ID: 1126582

  • 1. Group A streptococcal M protein vaccine: protection following immunization via the respiratory tract.
    Waldman RH, Lee JD, Polly SM, Dorfman A, Fox EN.
    Dev Biol Stand; 1975; 28():429-34. PubMed ID: 1126582
    [Abstract] [Full Text] [Related]

  • 2. Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers.
    Fox EN, Waldman RH, Wittner MK, Mauceri AA, Dorfman A.
    J Clin Invest; 1973 Aug; 52(8):1885-92. PubMed ID: 4719668
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus.
    D'Alessandri R, Plotkin G, Kluge RM, Wittner MK, Fox EN, Dorfman A, Waldman RH.
    J Infect Dis; 1978 Dec; 138(6):712-8. PubMed ID: 368261
    [Abstract] [Full Text] [Related]

  • 5. Protective immunity evoked by locally administered group A streptococcal vaccines in mice.
    Bronze MS, McKinsey DS, Beachey EH, Dale JB.
    J Immunol; 1988 Oct 15; 141(8):2767-70. PubMed ID: 3049817
    [Abstract] [Full Text] [Related]

  • 6. Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes.
    Bessen D, Fischetti VA.
    J Immunol; 1990 Aug 15; 145(4):1251-6. PubMed ID: 1696296
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection.
    Skelding KA, Hickey DK, Horvat JC, Bao S, Roberts KG, Finnie JM, Hansbro PM, Beagley KW.
    Vaccine; 2006 Jan 16; 24(3):355-66. PubMed ID: 16153755
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.
    McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J, Fries LF, Vink PE, Dale JB.
    Clin Infect Dis; 2005 Oct 15; 41(8):1114-22. PubMed ID: 16163629
    [Abstract] [Full Text] [Related]

  • 10. Immunization with bacterial antigens: infections with streptococci and related organisms.
    Bercovier H, Ghittino C, Eldar A.
    Dev Biol Stand; 1997 Oct 15; 90():153-60. PubMed ID: 9270844
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of Streptococcus agalactiae (group B) vaccine in tilapia (Oreochromis niloticus) by intraperitoneal and bath immersion administration.
    Evans JJ, Klesius PH, Shoemaker CA.
    Vaccine; 2004 Sep 09; 22(27-28):3769-73. PubMed ID: 15315858
    [Abstract] [Full Text] [Related]

  • 12. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice.
    Cleary PP, Matsuka YV, Huynh T, Lam H, Olmsted SB.
    Vaccine; 2004 Oct 22; 22(31-32):4332-41. PubMed ID: 15474726
    [Abstract] [Full Text] [Related]

  • 13. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study.
    Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SH, Ulrichs T, Novicki D, Norelli F, Contorni M, Peppoloni S, Berti D, Tornese D, Ganju J, Palla E, Rappuoli R, Scharschmidt BF, Del Giudice G.
    Gastroenterology; 2008 Sep 22; 135(3):787-95. PubMed ID: 18619971
    [Abstract] [Full Text] [Related]

  • 14. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S, Hinchcliffe M, Petrie CR, Warwood SJ, Tino WT, Williams MS, Stenz JP, Cheff A, Richardson C.
    Vaccine; 2006 May 01; 24(18):3953-63. PubMed ID: 16530302
    [Abstract] [Full Text] [Related]

  • 15. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.
    Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339
    [Abstract] [Full Text] [Related]

  • 16. Field evaluation of a commercial M-protein vaccine against Streptococcus equi infection in foals.
    Hoffman AM, Staempfli HR, Prescott JF, Viel L.
    Am J Vet Res; 1991 Apr 22; 52(4):589-92. PubMed ID: 2053730
    [Abstract] [Full Text] [Related]

  • 17. The anti-MAP and anti-group A carbohydrate antibodies response in streptococcal human infections.
    Mihalcu F, Stefãnescu M.
    Dev Biol Stand; 1975 Apr 22; 28():435-8. PubMed ID: 1126583
    [Abstract] [Full Text] [Related]

  • 18. Immunization with a Streptococcus bovis vaccine administered by different routes against lactic acidosis in sheep.
    Shu Q, Gill HS, Leng RA, Rowe JB.
    Vet J; 2000 May 22; 159(3):262-9. PubMed ID: 10775471
    [Abstract] [Full Text] [Related]

  • 19. [Local immunization against P. aeruginosa with an outer-membrane-protein vaccine].
    Grundmann T, Freihorst J, Kubesch P, Tümmler B, von der Hardt H.
    Pneumologie; 1991 Nov 22; 45(11):924-7. PubMed ID: 1763004
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of spheroplastic and cell-wall competent vaccines for Mycobacterium avium subsp. paratuberculosis in experimentally-challenged baby goats.
    Hines ME, Stiver S, Giri D, Whittington L, Watson C, Johnson J, Musgrove J, Pence M, Hurley D, Baldwin C, Gardner IA, Aly S.
    Vet Microbiol; 2007 Mar 10; 120(3-4):261-83. PubMed ID: 17123751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.